Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences, Inc. (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $142 billion, disclosed on Monday the departure of its Senior Vice President ...

NASDAQ GILD opened at $109.95 on Friday. The business has a 50 day simple moving average of $95.41 and a 200 day simple moving average of $88.63. Gilead Sciences has a 52-week low of $62.07 and a ...